Scholarlink

<p>Incretin-based obesity pharmacotherapies have revolutionized patient care but act predominantly by reducing food intake. Approaches that increase energy expenditure could improve efficacy but remain challenging to harness. Recently, neurokinin 2 receptor (NK2R) activation was shown to both lower food intake and stimulate energy expenditure in preclinical models. However, the endogenous NK2R ligand, NKA, crossreacts with other receptor family members that are linked to unwanted adverse effects. Therefore, understanding NK2R selectivity is the key to unlocking its therapeutic potential. Here we generated cryo-electron microscopy complexes of NK2R bound to NKA and several synthetic agonists to discover candidate interactions driving selectivity. Targeted receptor and ligand mutagenesis was then used to functionally validate the specific residues in the NK2R binding pocket and the C terminus of synthetic peptide agonists that were responsible for selectivity. These findings provide a structural framework for defining neurokinin selectivity and enable the development of improved NK2R agonists for clinical investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structurally defining neurokinin selectivity to improve NK2R agonists

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Artem Pavlovskyi,
  • Yinhang Ren,
  • María Gestal-Mato,
  • Ole H. Olsen,
  • Thue W. Schwartz,
  • Zachary Gerhart-Hines,
  • Xiangyu Liu

摘要

Incretin-based obesity pharmacotherapies have revolutionized patient care but act predominantly by reducing food intake. Approaches that increase energy expenditure could improve efficacy but remain challenging to harness. Recently, neurokinin 2 receptor (NK2R) activation was shown to both lower food intake and stimulate energy expenditure in preclinical models. However, the endogenous NK2R ligand, NKA, crossreacts with other receptor family members that are linked to unwanted adverse effects. Therefore, understanding NK2R selectivity is the key to unlocking its therapeutic potential. Here we generated cryo-electron microscopy complexes of NK2R bound to NKA and several synthetic agonists to discover candidate interactions driving selectivity. Targeted receptor and ligand mutagenesis was then used to functionally validate the specific residues in the NK2R binding pocket and the C terminus of synthetic peptide agonists that were responsible for selectivity. These findings provide a structural framework for defining neurokinin selectivity and enable the development of improved NK2R agonists for clinical investigation.